Clinically ineffective IGF1R-directed therapies may be associated with the ability of the cancer cell to re-activate the signaling pathway in addition to alternative activation of downstream IGF1R signaling pathways by other growth-promoting receptors in the cell such as HER2/3, EGFR and InsR [12, 36]. The gene discussed is IGF1R; the disease is cancer.